Share this article and save a life!
What if AI could catch the lung cancer your doctor missed?
New data from ARRS 2026 just stopped me in my tracks.
An FDA-cleared AI tool called qXR-LN improved detection of missed lung nodules on chest X-rays by 26.7%.
Think about that for a second.
More than 1 in 4 potentially cancerous nodules that human eyes missed, caught by AI.
The stakes couldn’t be higher:
• Early detection: 56% five-year survival rate
• Late detection: 5% five-year survival rate
That’s not a typo. It’s the difference between planning your future and planning your funeral.
Here’s what really struck me about the study:
73% of the missed nodules were in the upper lobes, the areas radiologists know are most challenging to read. The AI didn’t get tired. Didn’t get distracted. Didn’t have a bad day.
It just caught what humans missed.
💡 This isn’t about replacing radiologists. It’s about giving them superpowers.
As one researcher put it: “AI serves as a safety net, a second set of eyes.”
But here’s my question:
If we have technology that can catch 26.7% more lung cancers early, why isn’t every chest X-ray in America being double-checked by AI right now?
Is it regulatory barriers? Cost? Resistance to change?
Because while we debate, people are walking around with undetected lung nodules that could be treated today but might be terminal tomorrow.
The technology exists. The FDA has cleared it. The evidence is mounting.
What are we waiting for?
♻️ Repost if every chest X-ray deserves an AI second opinion
👉 Follow me, Jonathan Govette, for daily, real-time updates on healthcare technology and business news. LinkedIn Profile: https://www.linkedin.com/in/jonathangovette/
Share this article and save a life!
Author:
Jonathan Govette is a seasoned healthcare and technology executive with more than two decades of experience building, scaling, and advising digital health companies. He is the Co-Founder and CEO of Oatmeal Health, an AI-driven Lung Cancer Screening and Diagnostics company focused on expanding access to early detection for underrepresented populations, particularly patients served by Federally Qualified Health Centers and value-based health plans.
With a background in engineering, product development, and strategic partnerships, Jonathan has founded and led multiple health technology ventures across clinical care delivery, regulated medical software, and AI-enabled diagnostics. His work sits at the intersection of medicine, technology, and health equity, with a consistent focus on translating complex clinical problems into scalable, real-world solutions.
Jonathan has spent much of his professional life dedicated to improving outcomes for marginalized and underserved communities. He has designed and implemented frameworks that align clinical quality, reimbursement, and technology to sustainably advance health equity at scale. This mission is deeply personal and informs his leadership philosophy and long-term vision for healthcare transformation.
In addition to his operating experience, Jonathan is an author and long-time writer in the healthcare domain, with over 20 years of published work covering digital health, medical innovation, and healthcare systems. He is a frequent mentor to early-stage founders and regularly advises startups on product strategy, partnerships, and go-to-market execution in regulated healthcare environments.
Before entering industry full-time, Jonathan nearly pursued a career in medicine with an early path toward cardiothoracic surgery, an experience that continues to shape his clinical perspective and respect for frontline care delivery.
CEO | Oatmeal Health | AI Lung Cancer Startup | Engineer | Writer | Almost Became a Doctor (Cardiac Thoracic Surgeon) | 3x Health Tech Founder | Startup Mentor | Follow to share what I’ve learned along the way.
